Pharmaceutical company warehouse logistics electronic label technical reform through the acceptance
Release time:
2020-08-14
Pharmaceutical Company Warehouse Logistics Electronic Label Technical Transformation Passed Acceptance
News 11# July 2 , Jinhua Pharmaceutical Company Warehouse Logistics Electronic Label Technical Transformation Project successfully passed the acceptance of the Group Company Project Acceptance Team. The electronic label technical renovation project of
pharmaceutical company started construction at the end of 2016 9 . the software and hardware installation of the whole project was basically completed in late 2016 10 , and the system was put into trial operation. In view of the problems in the trial operation, the pharmaceutical company improved while running, focusing on solving the problem of unsmooth data transmission in the software interface connection between WMS and ERP system, and the whole system remained normal and stable.
This project re-plans and designs the process layout of each floor of the warehouse. The entire warehouse is divided into a bulk warehouse and a whole warehouse. Reinstall the hardware facilities and equipment such as shelf storage, sorting, review, air cooler, turnover box, etc. At the same time, the warehouse management system (WMS) software is connected with the original computer business management system (ERP ).
WMS system location management divides the warehouse into several management areas according to floors and warehouses in the system, and each area is divided into several locations according to channels, corresponding to unique location bar codes; According to the drug dosage form, specification, batch number and other attributes to reasonably allocate storage space, realize the tracking management of drugs; Through bar code management, warehouse storage and warehouse delivery are established, moving warehouse, inventory data, etc., processing and collecting data, can provide warehouse location information for warehouse goods according to the goods inventory, so that the warehouse goods inventory is more accurate, to ensure the warehouse into, sell, store reasonable. After the
WMS is integrated with the ERP system, all-round docking of basic, incoming and outgoing, inventory and other data is realized. In daily operations, the ERP system issues system operation instructions such as inbound and outbound, and the WMS automatically issues system operation instructions such as inbound and outbound after receiving them through the system interface to complete the warehouse's purchase, sale and inventory management. WMS After completing the system operation instruction, the relevant information will be transmitted back to ERP through the system interface to realize synchronous data docking between the two sides, the whole process of drug storage and delivery is carried out through handheld computer terminals and electronic labels. The location management function and bar code management of
WMS solve the deficiency of the inventory management function of ERP in pharmaceutical companies, and carry out real-time data collection and quality traceability for the whole process. Using the electronic label location management function and using the electronic label to pick goods can automatically display information such as drug location and quantity, thus reducing the time for finding goods in the staff warehouse and improving the working efficiency of warehouse logistics; due to the automatic addressing function of WMS system for drug warehousing and outbound and the accurate positioning of electronic labels, the error rate in the warehousing and outbound operation process is reduced, the drug quality is ensured and the requirements of GSP are met, and at the same time, some hardware management of drug warehousing in pharmaceutical companies meets the storage hardware licensing standards of drug wholesale enterprises in Zhejiang Province. (Jiang Xiaohua)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page